propylamines

Summary

Top Publications

  1. ncbi Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 27:699-711. 2002
  2. ncbi Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline
    Tobias Banaschewski
    Dept of Child and Adolescent Psychiatry Psychotherapy, University of Goettingen, Von Siebold Str 5, 37075 Goettingen, Germany
    Eur Child Adolesc Psychiatry 15:476-95. 2006
  3. pmc European guidelines on managing adverse effects of medication for ADHD
    J Graham
    Child and Adolescent Psychiatry, The Centre for Child Health, Dundee, UK
    Eur Child Adolesc Psychiatry 20:17-37. 2011
  4. ncbi Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database
    Suzanne McCarthy
    Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London and the Institute of Child Health, University College London, London, UK
    Drug Saf 32:1089-96. 2009
  5. ncbi Attention deficit hyperactivity disorder in adults
    Michael Rösler
    Neurozentrum, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    World J Biol Psychiatry 11:684-98. 2010
  6. ncbi Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone
    Neil E Paterson
    Behavioral Pharmacology, PsychoGenics, Inc, Tarrytown, NY 10591, USA
    Neurosci Res 69:41-50. 2011
  7. pmc Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence
    Suzanne McCarthy
    School of Pharmacy, University College Cork, Cork, Ireland
    BMC Psychiatry 12:219. 2012
  8. ncbi Dynamics of membrane protein/amphipol association studied by Förster resonance energy transfer: implications for in vitro studies of amphipol-stabilized membrane proteins
    Manuela Zoonens
    Laboratoire de Physico Chimie Moléculaire des Membranes Biologiques, UMR 7099, Centre National de la Recherche Scientifique, and Institut de Biologie Physico Chimique, Universite Paris 7, 13 rue Pierre et Marie Curie, F 75005 Paris, France
    Biochemistry 46:10392-404. 2007
  9. ncbi Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines
    Josep Antoni Ramos-Quiroga
    Adult ADHD Program, Department of Psychiatry, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Curr Med Res Opin 29:1093-104. 2013
  10. ncbi Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder
    Samuel R Chamberlain
    Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    Biol Psychiatry 62:977-84. 2007

Research Grants

  1. LONG TERM DRUG ABUSE IN ADHD
    Timothy Wilens; Fiscal Year: 2002
  2. Substance Abuse in ADHD Girls
    Timothy Wilens; Fiscal Year: 2006
  3. Juvenile Bipolar Disorder and Substance Abuse
    Timothy E Wilens; Fiscal Year: 2010
  4. Pharmacological Treatment of ADHD in Young Children
    Christopher Kratochvil; Fiscal Year: 2007
  5. Dopamine and ADHD: A Research Infrastructure Network
    Jeffrey Newcorn; Fiscal Year: 2004
  6. Predicting Response to Atomoxetine and Methlyphenidate
    Jeffrey Newcorn; Fiscal Year: 2009
  7. NEUROIMAGING OF INHIBITION & STIMULANT RESPONSE IN ADHD
    Steven Pliszka; Fiscal Year: 2004
  8. Dopamine Transporter Binding by PET in Adult ADHD
    Thomas Spencer; Fiscal Year: 2007
  9. CONTROLLED STUDY OF METHYLPHENIDATE IN ADULTS WITH ADHD
    Thomas Spencer; Fiscal Year: 2002
  10. Pimozide Augmentation of Clozapine in Schizophrenia
    Joseph Friedman; Fiscal Year: 2007

Detail Information

Publications233 found, 100 shown here

  1. ncbi Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 27:699-711. 2002
    ..In contrast to methylphenidate, atomoxetine did not increase DA in striatum or nucleus accumbens, suggesting it would not have motoric or drug abuse liabilities...
  2. ncbi Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline
    Tobias Banaschewski
    Dept of Child and Adolescent Psychiatry Psychotherapy, University of Goettingen, Von Siebold Str 5, 37075 Goettingen, Germany
    Eur Child Adolesc Psychiatry 15:476-95. 2006
    ..Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made...
  3. pmc European guidelines on managing adverse effects of medication for ADHD
    J Graham
    Child and Adolescent Psychiatry, The Centre for Child Health, Dundee, UK
    Eur Child Adolesc Psychiatry 20:17-37. 2011
    ..Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks...
  4. ncbi Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database
    Suzanne McCarthy
    Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London and the Institute of Child Health, University College London, London, UK
    Drug Saf 32:1089-96. 2009
    ....
  5. ncbi Attention deficit hyperactivity disorder in adults
    Michael Rösler
    Neurozentrum, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    World J Biol Psychiatry 11:684-98. 2010
    ..To examine available literature regarding attention deficit hyperactivity disorder (ADHD) in adults...
  6. ncbi Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone
    Neil E Paterson
    Behavioral Pharmacology, PsychoGenics, Inc, Tarrytown, NY 10591, USA
    Neurosci Res 69:41-50. 2011
    ..Finally, tolcapone had no effects on sub-optimal performance in the variable ITI 5-CSRTT. These results suggest minimal potential of tolcapone as a therapeutic agent for ADHD and implicate cortical NE, not DA, in impulsive action...
  7. pmc Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence
    Suzanne McCarthy
    School of Pharmacy, University College Cork, Cork, Ireland
    BMC Psychiatry 12:219. 2012
    ....
  8. ncbi Dynamics of membrane protein/amphipol association studied by Förster resonance energy transfer: implications for in vitro studies of amphipol-stabilized membrane proteins
    Manuela Zoonens
    Laboratoire de Physico Chimie Moléculaire des Membranes Biologiques, UMR 7099, Centre National de la Recherche Scientifique, and Institut de Biologie Physico Chimique, Universite Paris 7, 13 rue Pierre et Marie Curie, F 75005 Paris, France
    Biochemistry 46:10392-404. 2007
    ..These findings are discussed in the contexts of sample optimization for MP solution studies and of APol-mediated MP functionalization...
  9. ncbi Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines
    Josep Antoni Ramos-Quiroga
    Adult ADHD Program, Department of Psychiatry, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Curr Med Res Opin 29:1093-104. 2013
    ..Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobiological disorder with childhood onset and persistence into adolescence and adulthood...
  10. ncbi Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder
    Samuel R Chamberlain
    Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    Biol Psychiatry 62:977-84. 2007
    ..Compared with psychostimulants, atomoxetine has a distinct mode of brain action and potentially lower addictive potential. Studies have yet to assess whether atomoxetine improves cognition following a single oral dose in ADHD...
  11. ncbi Atomoxetine and cerebrovascular outcomes in adults
    Crystal N Holick
    i3 Drug Safety, Waltham, MA, USA
    J Clin Psychopharmacol 29:453-60. 2009
    ..The aim of this study was to estimate the association between atomoxetine and cerebrovascular accident (CVA) and transient ischemic attack (TIA) in adults...
  12. ncbi Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome
    Thomas J Spencer
    Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Atten Disord 11:470-81. 2008
    ..This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS)...
  13. ncbi A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder
    Michihiro Takahashi
    Lilly Research Laboratories Japan, Kobe, Japan E mail
    J Child Adolesc Psychopharmacol 19:341-50. 2009
    ..This first placebo-controlled Japan study of an ADHD nonstimulant therapy assessed atomoxetine efficacy and safety to determine the optimal dose for controlling ADHD symptoms in children and adolescents...
  14. ncbi Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers
    Heiko Graf
    Department of Psychiatry, Ulm University Hospital, Ulm University, Ulm, Germany
    Biol Psychiatry 69:890-7. 2011
    ..We investigated the effects of atomoxetine (80 mg) on error monitoring as a second key component of cognitive control...
  15. pmc Bacteriorhodopsin/amphipol complexes: structural and functional properties
    Yann Gohon
    Laboratoire de Physico Chimie Moléculaire des Membranes Biologiques, Centre National de la Recherche Scientifique, and Université Paris 7, Institut de Biologie Physico Chimique, Paris, France
    Biophys J 94:3523-37. 2008
    ..In the absence of free APol, BR/APol particles can autoassociate into small or large ordered fibrils...
  16. pmc Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers
    Andre F Marquand
    Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, King s College London, London, UK
    Neuropsychopharmacology 36:1237-47. 2011
    ..Thus, interactions between drug effects and motivational state are crucial in defining the effects of MPH and ATX...
  17. ncbi Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study
    Samuel R Chamberlain
    Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, University of Cambridge, Cambridge, UK
    Biol Psychiatry 65:550-5. 2009
    ..However, the mechanisms by which atomoxetine improves inhibitory control have yet to be determined...
  18. ncbi Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test
    Rachel Navarra
    Discovery Neuroscience, Wyeth Research, 500 Arcola Road, PA 19426 USA
    Prog Neuropsychopharmacol Biol Psychiatry 32:34-41. 2008
    ..Those data suggest that the 5CSRT test can be used to differentiate stimulant and non-stimulant pharmacotherapies on measures of impulsivity...
  19. ncbi Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management
    Johnny Graham
    Child and Adolescent Psychiatry, University of Dundee, Section of Psychiatry, Division of Pathology and Neuroscience, Ninewells Hospital, Dundee, Scotland
    CNS Drugs 22:213-37. 2008
    ..For example, the latter shares the stimulant group's potential for changing cardiovascular parameters, but may not cause insomnia...
  20. ncbi New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD
    D J Heal
    RenaSci Consultancy Limited, BioCity, Nottingham NG1 1GF, UK
    Pharmacol Biochem Behav 90:184-97. 2008
    ..When the findings are compared with the clinical efficacy of drugs used in treating ADHD, they indicate that the most efficacious drugs powerfully increase both norepinephrinergic and dopaminergic neurotransmission...
  21. ncbi Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder
    Gary Stiefel
    St Mary s Hospital, London, UK
    Drug Saf 33:821-42. 2010
    ....
  22. pmc Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats
    Petra J J Baarendse
    Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, UMC Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands
    Psychopharmacology (Berl) 219:313-26. 2012
    ..However, impulsive behavior is behaviorally and neurally heterogeneous, and several caveats remain in our understanding of the role of monoamines in impulse control...
  23. pmc Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine
    Timothy E Wilens
    Massachusetts General Hospital, Boston, MA 02114, USA
    Curr Med Res Opin 27:2309-20. 2011
    ..Attention-deficit/hyperactivity disorder (ADHD) and substance use disorder are often comorbid in adults. The effects of ADHD treatment on comorbid alcohol use disorder have not been extensively studied...
  24. ncbi Well-defined critical association concentration and rapid adsorption at the air/water interface of a short amphiphilic polymer, amphipol A8-35: a study by Förster resonance energy transfer and dynamic surface tension measurements
    Fabrice Giusti
    UMR 7099, CNRS Université Paris 7, Institut de Biologie Physico Chimique, 13 rue Pierre et Marie Curie, F 75005 Paris, France
    Langmuir 28:10372-80. 2012
    ....
  25. pmc Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats
    Andrea Bari
    Department of Experimental Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Downing Street, Cambridge CB23EB, UK
    Psychopharmacology (Berl) 205:273-83. 2009
    ..While there is relative consensus regarding the anatomical substrates of behavioral inhibition, the neurochemical imbalance responsible for the deficits in stopping displayed by impulsive individuals is still a matter of debate...
  26. ncbi Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands
    Paul Hodgkins
    Global Health Economics and Outcomes Research, Shire Development Inc, Wayne, Pennsylvania 19087 5637, USA
    Clin Ther 33:188-203. 2011
    ....
  27. ncbi Novel treatments for attention-deficit/hyperactivity disorder in children
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 63:16-22. 2002
    ....
  28. pmc Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors
    Nao J Gamo
    Yale University School of Medicine, New Haven, CT, USA
    J Am Acad Child Adolesc Psychiatry 49:1011-23. 2010
    ....
  29. pmc The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care
    Suzanne McCarthy
    School of Pharmacy, University College Cork, Cork, Ireland
    BMC Pediatr 12:78. 2012
    ..The aim of this study was to investigate the annual prevalence and incidence of pharmacologically treated ADHD in children, adolescents and adults in UK primary care...
  30. pmc Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents
    Pär Svanborg
    Eli Lilly Sweden AB, Box 721, 169 27 Solna, Sweden
    Eur Child Adolesc Psychiatry 18:725-35. 2009
    ....
  31. ncbi Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder
    Kiki Chang
    Pediatric Bipolar Disorders Program, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA
    J Child Adolesc Psychopharmacol 19:547-51. 2009
    ..We conducted an 8-week, open label study to study the efficacy and tolerability of adjunct atomoxetine in euthymic children and adolescents with BPD and ADHD...
  32. ncbi Atomoxetine use associated with onset of a motor tic
    Marcialee Ledbetter
    Department of Psychiatry and Pediatrics, University of Oklahoma Tulsa, Tulsa, Oklahoma 74135, USA
    J Child Adolesc Psychopharmacol 15:331-3. 2005
    ..Further research is needed to determine if atomoxetine is an appropriate alternative medication in patients with ADHD and a comorbid tic disorder...
  33. ncbi Medications do not necessarily normalize cognition in ADHD patients
    C Thomas Gualtieri
    North Carolina Neuropsychiatry Clinics, Chapel Hill, NC 27514, USA
    J Atten Disord 11:459-69. 2008
    ..Although ADHD medications are effective for the behavioral components of the disorder, little information exists concerning their effects on cognition, especially in community samples...
  34. ncbi Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder
    Alonso Montoya
    Clinical Research, Lilly Research Laboratories, Avenida Industria 30, Alcobendas, Spain
    Curr Med Res Opin 25:2745-54. 2009
    ..To test the hypothesis that first-line treatment with atomoxetine provides superior efficacy than placebo for up to 12 weeks in improving the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD)...
  35. pmc Neurochemical modulation of response inhibition and probabilistic learning in humans
    Samuel R Chamberlain
    Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Box 189, Cambridge CB2 2QQ, UK
    Science 311:861-3. 2006
    ....
  36. ncbi Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex
    Donald L Gilbert
    Division of Neurology, Cincinnati Children s Hospital Medical Center, University of Cincinnati, OH 45229, USA
    Neuropsychopharmacology 31:442-9. 2006
    ..Cortical inhibition, shown previously to be abnormal in ADHD, may play a key role producing behavioral pathology...
  37. ncbi Cardiovascular effects of atomoxetine in children, adolescents, and adults
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Drug Saf 26:729-40. 2003
    ..Adverse effects on the cardiovascular system, including abnormalities in heart rate, blood pressure, or cardiac rhythm have been associated with several noradrenergic medications...
  38. ncbi Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine
    Joachim F Wernicke
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    Dev Med Child Neurol 49:498-502. 2007
    ..The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD...
  39. ncbi Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, Department of Psychiatry, Boston, Massachusetts, USA
    J Pediatr 149:112-9. 2006
    ..To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years...
  40. ncbi Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study
    Jason E Kemner
    McNeil Consumer and Specialty Pharmaceuticals, Fort Washington, Pennsylvania 19034, USA
    Adv Ther 22:498-512. 2005
    ..Although community-based studies often lack the control of randomized, placebo-controlled trials, these results nevertheless suggest greater ADHD symptom improvement with OROS MPH compared with atomoxetine...
  41. ncbi Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing
    Stan L Block
    Kentucky Pediatric Research, Bardstown, Kentucky 40004, USA
    Clin Pediatr (Phila) 48:723-33. 2009
    ..Evening dosing showed greater tolerability with significantly more patients receiving morning atomoxetine reporting at least 1 adverse event than those receiving evening atomoxetine...
  42. pmc Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim
    Rui Jun Zhao
    Department of Environmental Medicine, Institute of Health and Environmental Medicine, Academy of Military Medical Sciences, Beijing 100850, China
    Acta Pharmacol Sin 32:573-80. 2011
    ..To elucidate the modulation of the chemerin/ChemR23 axis by iptakalim-induced opening of K(ATP) channels and to determine the role of the chemerin/ChemR23 axis in the iptakalim-mediated endothelial protection...
  43. ncbi Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice
    Ken Koda
    Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565 0871, Japan
    J Neurochem 114:259-70. 2010
    ..These results suggest that acute and chronic administration of the ADHD drugs selectively activate the prefrontal catecholamine systems in mice...
  44. ncbi Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 64:205-22. 2004
    ..This also means repeat prescriptions during long-term treatment can be more conveniently processed...
  45. ncbi Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo
    Jan K Buitelaar
    Department of Psychiatry, Radboud University Nijmegen Medical Centre and Karakter University Centre for Child and Adolescent Psychiatry, Nijmegen, The Netherlands
    J Child Psychol Psychiatry 50:335-42. 2009
    ....
  46. ncbi Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder
    S Kaplan
    Penn State Hershey Medical Center, Department of Psychiatry, Hershey, PA 17033, USA
    J Atten Disord 8:45-52. 2004
    ..To compare the safety and efficacy of atomoxetine, a selective inhibitor of the norepinephrine transporter, versus placebo in Attention-Deficit/Hyperactivity Disorder (ADHD) patients with comorbid Oppositional Defiant Disorder (ODD)...
  47. ncbi Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder
    Gabriel Kaplan
    Department of Psychiatry, Hoboken University Medical Center, Hoboken, NJ 07030, USA
    Pediatr Clin North Am 58:99-120, xi. 2011
    ..In addition, it addresses treatment selection, guidelines for monitoring treatment, and recent controversies in the field...
  48. ncbi Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys
    Maciej Gasior
    McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Neuropsychopharmacology 30:758-64. 2005
    ..The absence of reinforcing effects of atomoxetine support the view that, like desipramine, it has no evident abuse potential...
  49. pmc Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine
    Delia F Tifrea
    Department of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA 92697 4800, USA
    Vaccine 29:4623-31. 2011
    ..Thus, amphipols can be used in vaccine formulations to stabilize a membrane-protein component and enhance its immunogenicity...
  50. ncbi Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat
    Emma S J Robinson
    Department of Experimental Psychology, Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 33:1028-37. 2008
    ....
  51. ncbi Hemodynamic effects of acute administration of atomoxetine and methylphenidate
    Ronan P Kelly
    Lilly NUS Centre for Clinical Pharmacology, Level 6 Clinical Research Centre MD11, National University of Singapore, Singapore
    J Clin Pharmacol 45:851-5. 2005
  52. ncbi Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder
    Rodrigo Escobar
    EU Medical, Lilly Research Laboratories, Alcobendas, Spain
    J Child Adolesc Psychopharmacol 19:253-63. 2009
    ..The aim of this study was to demonstrate the superior efficacy of atomoxetine with respect to placebo and to compare parent and child perceptions of health-related quality of life (HRQoL)...
  53. ncbi Amphipol-assisted folding of bacteriorhodopsin in the presence or absence of lipids: functional consequences
    Tassadite Dahmane
    UMR 7099, CNRS Université Paris 7, Institut de Biologie Physico Chimique, 13 rue Pierre et Marie Curie, 75005, Paris, France
    Eur Biophys J 42:85-101. 2013
    ..BR interactions with lipids, however, contribute to an effective photocycle...
  54. ncbi Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans
    Joshua A Lile
    Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, 40536 0086, USA
    Exp Clin Psychopharmacol 14:136-47. 2006
    ..These data suggest that the behavioral effects of atomoxetine overlap to a small degree with psychomotor stimulants and that it has low abuse potential...
  55. ncbi Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis IN 46285, USA
    J Clin Psychopharmacol 24:30-5. 2004
    ..It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects. Tapering of doses is not necessary when atomoxetine is discontinued...
  56. ncbi Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders
    Timothy E Wilens
    Massachusetts General Hospital, 55 Fruit Street, YAW 6900, Boston, MA 02114, USA
    Drug Alcohol Depend 96:145-54. 2008
    ..The study aim was to determine if atomoxetine was superior to placebo in improving ADHD and alcohol use in recently abstinent adults with ADHD and comorbid alcohol use disorder...
  57. pmc Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys
    Emanuele Seu
    Department of Psychology, University of California Los Angeles, P O Box 951563, Los Angeles, CA 90095 1563, USA
    Psychopharmacology (Berl) 202:505-19. 2009
    ....
  58. ncbi Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder
    Stephen V Faraone
    Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, New York 13210, USA
    J Child Adolesc Psychopharmacol 15:664-70. 2005
    ..The aim of this study was to assess the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, for executive functioning in adults with attention-deficit/hyperactivity disorder (ADHD)...
  59. ncbi Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine
    Sunmee Wee
    Department of Psychiatry and Human Behavior, Division of Neurobiology and Behavior Research, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS 39216, USA
    Drug Alcohol Depend 75:271-6. 2004
    ..These results predict that atomoxetine, in contrast to methylphenidate but like desipramine, will lack reinforcing effects and abuse potential in humans...
  60. ncbi Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study
    Sean Hennessy
    Center for Clinical Epidemiology and Biostatistics, and Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Pharmacoepidemiol Drug Saf 19:934-41. 2010
    ....
  61. ncbi Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database
    Almut G Winterstein
    Department of Healthcare Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    Ann Pharmacother 42:24-31. 2008
    ..Little is known about longitudinal changes in drug utilization in attention-deficit/hyperactivity disorder (ADHD)...
  62. ncbi A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)
    Nicolas Ramoz
    INSERM U675, IFR02, Faculty Xavier Bichat, University of Paris, Paris, France
    Neuropsychopharmacology 34:2135-42. 2009
    ....
  63. ncbi Atomoxetine
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:407-15; discussion 416-7. 2003
    ..The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled substance in the US...
  64. ncbi CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD
    David Michelson
    Lilly Research Laboratories, Indianapolis, USA
    J Am Acad Child Adolesc Psychiatry 46:242-51. 2007
    ..Variations in plasma atomoxetine exposures can occur because of genetic variation or as a consequence of coadministration with drugs that inhibit CYP2D6...
  65. ncbi Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial
    K M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, NC 27710, USA
    Int J Obes (Lond) 30:1138-42. 2006
    ..With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults...
  66. ncbi Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder
    Robert J Barry
    Brain and Behaviour Research Institute and School of Psychology, University of Wollongong, Wollongong 2522, Australia
    Neuropharmacology 57:702-7. 2009
    ....
  67. ncbi Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents
    Karly P Garnock-Jones
    Adis, a Wolters Kluwer Business, Mairangi Bay, North Shore, Auckland, New Zealand
    CNS Drugs 24:85-8. 2010
    ..Thus, atomoxetine is a useful option in the treatment of ADHD in children and adolescents...
  68. ncbi Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder
    Philip Hazell
    University of Newcastle and Wallsend Hospital, Child and Youth Mental Health Service, Newcastle, NSW, Australia
    Australas Psychiatry 12:369-75. 2004
    ....
  69. ncbi Atomoxetine and tics in ADHD
    Tih Shih W Lee
    J Am Acad Child Adolesc Psychiatry 43:1068-9. 2004
  70. ncbi Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:919-27. 2006
    ....
  71. pmc Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders
    Amy F T Arnsten
    Department of Neurobiology, Yale University School of Medicine, New Haven, CT 06510, USA
    Pharmacol Biochem Behav 99:211-6. 2011
    ..Stronger PFC regulation of attention, behavior, and emotion likely contributes to the therapeutic effects of these medications for the treatment of ADHD...
  72. ncbi Dimensional analysis of ADHD subtypes in rats
    Candice Blondeau
    Hôpital Charles Perrens, Laboratoire de Neuropsychobiologie des Desadaptations, Université Victor Segalen Bordeaux 2 CNRS UMR 554 1, Bordeaux, France
    Biol Psychiatry 61:1340-50. 2007
    ..The nature of the biological dysfunction sustaining each subtype (common or distinct) is unknown, and animal models encompassing different subtypes are needed...
  73. ncbi Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults
    Suzanne McCarthy
    Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London and Institute of Child Health, University College London, UK
    Br J Psychiatry 194:273-7. 2009
    ..Symptoms of attention-deficit hyperactivity disorder (ADHD) are known to persist into adulthood in the majority of cases...
  74. ncbi Electrochemiluminescence from hydrophilic thin film Ru(bpy)3(2+)-modified electrode prepared using natural halloysite nanotubes and polyacrylamide gel
    Bo Xing
    Research Center for Analytical Sciences, College of Chemistry, Nankai University, Tianjin, 300071, China
    Biosens Bioelectron 24:2939-42. 2009
    ..Contrary to the previous works, the addition of carbon nanotubes into the modified electrode film leads to a decreased ECL emission, due to the reduction in the porosity of the film, which hinders the diffusion of the analyte...
  75. ncbi Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects
    G E Boeckxstaens
    Academic Medical Center, Amsterdam, The Netherlands
    Aliment Pharmacol Ther 31:1208-17. 2010
    ..Transient lower oesophageal sphincter relaxations (TLESRs) are a major mechanism behind gastro-oesophageal reflux disease (GERD)...
  76. ncbi Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex
    Weldon E Horner
    Department of Neuroscience, MS 8220 4159, Pfizer Global Research and Development, Groton, CT 06340 USA
    Eur J Pharmacol 558:96-7. 2007
    ..While the clinical response to ADHD drugs is typically attributed to modulation of norepinephrine and dopamine, this finding suggests enhanced histamine release may contribute to their efficacy as ADHD treatments...
  77. ncbi Abuse liability assessment of atomoxetine in a drug-abusing population
    Donald R Jasinski
    Johns Hopkins School of Medicine, Center for Chemical Dependence, 4940 Eastern Avenue, Baltimore, MD 21224, USA
    Drug Alcohol Depend 95:140-6. 2008
    ..This study assessed the abuse potential of atomoxetine in stimulant-preferring drug abusers compared to methylphenidate and phentermine as positive controls and desipramine and placebo as negative controls...
  78. ncbi Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Am Acad Child Adolesc Psychiatry 48:511-8. 2009
    ..We conducted a retrospective analysis of randomized controlled trials (RCTs) to identify potential baseline (moderator) and on-treatment (mediator) predictors of responses...
  79. ncbi The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database
    Andrew T McAfee
    1i3 Drug Safety, Waltham, Massachusetts, USA
    Curr Drug Saf 3:123-31. 2008
    ..To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy...
  80. ncbi Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder
    Joseph Biederman
    Massachusetts General Hospital, ACC 725, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 7:77-97. 2004
    ..Further, more research is needed on the efficacy of treatment for comorbid ADHD, use of combined medications, and the combination of medication and psychosocial treatment...
  81. ncbi Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder
    Humberto C Párraga
    Fourth Street Clinic, Springfield, Illinois 62703, USA
    Int J Psychiatry Med 37:415-24. 2007
    ..Independent controlled studies are needed to determine if atomoxetine should be used in children with ADHD and comorbid tic disorders or TS...
  82. ncbi Iptakalim, a vascular ATP-sensitive potassium (KATP) channel opener, closes rat pancreatic beta-cell KATP channels and increases insulin release
    Naoko Misaki
    Department of Physiology, Hirosaki University School of Medicine, Zaifucho, Japan
    J Pharmacol Exp Ther 322:871-8. 2007
    ....
  83. ncbi A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats
    Hao Xue
    Department of Cardiovascular Pharmacology, Beijing Institute of Pharmacology and Toxicology, People s Republic of China
    J Pharmacol Exp Ther 315:501-9. 2005
    ....
  84. ncbi Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis
    Jackie Y W Cheng
    Department of Psychiatry, University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
    Psychopharmacology (Berl) 194:197-209. 2007
    ..The objective of this study was to evaluate the efficacy and safety of atomoxetine in children and adolescents...
  85. ncbi Development of tics in a thirteen-year-old male following atomoxetine use
    Jessica Sears
    Pediatric Neurology, Department of Child Health, University of Missouri Columbia, Columbia, MO 65212, USA
    CNS Spectr 13:301-3. 2008
    ..We present a unique case of a patient, without any prior history of a movement disorder, who developed tics following a single dose of atomoxetine that did not improve until interventional therapy was initiated...
  86. ncbi Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial
    Christopher J Kratochvil
    University of Nebraska Medical Center, USA
    J Am Acad Child Adolesc Psychiatry 41:776-84. 2002
    ..Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.)..
  87. ncbi Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder
    Daniel Geller
    Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, 185 Alewife Brook Parkway, Cambridge, MA 02138, USA
    J Am Acad Child Adolesc Psychiatry 46:1119-27. 2007
    ....
  88. ncbi [Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample]
    R Escobar
    Departamento Médico, Lilly Research Laboratories, Alcobendas, Madrid
    Actas Esp Psiquiatr 33:26-32. 2005
    ....
  89. ncbi A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
    Jan K Buitelaar
    Department of Psychiatry, University Medical Center Nijmegen, 9101, 6500, HB Nijmegen, The Netherlands
    Eur Child Adolesc Psychiatry 13:249-57. 2004
    ..The aim of this study was to study treatment response to atomoxetine in a large, multicenter study of non-North American patients with ADHD...
  90. pmc Association of the antihypertensive response of iptakalim with KCNJ11 (Kir6.2 gene) polymorphisms in Chinese Han hypertensive patients
    Rui Feng Duan
    Cardiovascular Drug Research Center, Institute of Health and Environmental Medicine, Academy of Military Medical Sciences, Beijing, China
    Acta Pharmacol Sin 32:1078-84. 2011
    ..To study the relationship between the antihypertensive response of iptakalim and KCNJ11 polymorphisms in Chinese Han hypertensive patients...
  91. ncbi Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents
    Pär Svanborg
    Eli Lilly Sweden AB, Gustav III Boulevard 42, Box 721, 169 27, Solna, Sweden
    Eur Child Adolesc Psychiatry 18:240-9. 2009
    ..HRQL results will be presented elsewhere. Here, psychoeducation as well as efficacy and safety of the treatment are described...
  92. ncbi Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users
    S H Heil
    Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA
    Drug Alcohol Depend 67:149-56. 2002
    ..These results suggest that atomoxetine does not induce subjective effects similar to methylphenidate and suggest that it is unlikely that atomoxetine will have abuse liability...
  93. ncbi Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
    ..The present work examined suicide-related events in acute, double-blind, and placebo- or active comparator-controlled trials with atomoxetine...
  94. ncbi Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease
    Guy E Boeckxstaens
    Academic Medical Centre, Amsterdam, The Netherlands
    Gastroenterology 139:409-17. 2010
    ....
  95. ncbi Dopamine transporter genotype influences the physiological response to medication in ADHD
    Donald L Gilbert
    Division of Neurology Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Brain 129:2038-46. 2006
    ..In conclusion, MPH and ATX have similar effects on SICI in children with ADHD. A genetic variation in DAT1, previously linked to ADHD risk and MPH behavioural responses, influences the neurophysiological effects of both MPH and ATX...
  96. ncbi Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Massachusetts General Hospital, Boston, MA 02114, USA
    Pediatrics 116:e74-80. 2005
    ..This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder...
  97. ncbi Atomoxetine and tics in ADHD
    Peter D Feldman
    J Am Acad Child Adolesc Psychiatry 44:405-6. 2005
  98. ncbi Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder
    Aaron P Gibson
    College of Pharmacy, The University of Texas at Austin, 78712, USA
    Ann Pharmacother 40:1134-42. 2006
    ..To identify, review, and analyze studies comparing atomoxetine with psychostimulants with the intent of determining the role of atomoxetine in the pharmacologic management of attention deficit/hyperactivity disorder (ADHD)...
  99. ncbi Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder
    Brigette Vaughan
    Nebraska Medical Center, Department of Psychiatry, Omaha, NE 68198, USA
    Expert Opin Pharmacother 10:669-76. 2009
    ..Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety...
  100. pmc Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder
    Jaswinder K Ghuman
    Department of Psychiatry, University of Arizona, Tucson, Arizona 85724 5002, USA
    J Child Adolesc Psychopharmacol 19:155-66. 2009
    ..The aim of this study was to report preliminary data regarding effectiveness and tolerability of atomoxetine in 3- to 5-year-old preschool children with attention-deficit/hyperactivity disorder (ADHD)...
  101. ncbi Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
    David Michelson
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 53:112-20. 2003
    ..To assess the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, we conducted two large, multicenter treatment trials...

Research Grants62

  1. LONG TERM DRUG ABUSE IN ADHD
    Timothy Wilens; Fiscal Year: 2002
    ..abstract_text> ..
  2. Substance Abuse in ADHD Girls
    Timothy Wilens; Fiscal Year: 2006
    ..Thus, the research, approach, and goals of this R01 application are consistent with those underscored in the PA and by the Institute of Medicine as being of the highest research priority. ..
  3. Juvenile Bipolar Disorder and Substance Abuse
    Timothy E Wilens; Fiscal Year: 2010
    ..Since BPD is identifiable and treatable, findings from the four-year follow-up will provide valuable information to formulate prevention and early intervention strategies. ..
  4. Pharmacological Treatment of ADHD in Young Children
    Christopher Kratochvil; Fiscal Year: 2007
    ..abstract_text> ..
  5. Dopamine and ADHD: A Research Infrastructure Network
    Jeffrey Newcorn; Fiscal Year: 2004
    ..In addition, the post-doctoral students will be able to spend time in multiple laboratories, which will facilitate the transfer of key theoretical and technical expertise across sites. ..
  6. Predicting Response to Atomoxetine and Methlyphenidate
    Jeffrey Newcorn; Fiscal Year: 2009
    ..abstract_text> ..
  7. NEUROIMAGING OF INHIBITION & STIMULANT RESPONSE IN ADHD
    Steven Pliszka; Fiscal Year: 2004
    ..5) We will control for effects of gender and age, in particular girls with ADHD may not show the same neurobiological mechanisms as boys. ..
  8. Dopamine Transporter Binding by PET in Adult ADHD
    Thomas Spencer; Fiscal Year: 2007
    ..qenetic risk factors, a) We hypothesize that DAT binding will be associated with the 480 allele of the 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene. ..
  9. CONTROLLED STUDY OF METHYLPHENIDATE IN ADULTS WITH ADHD
    Thomas Spencer; Fiscal Year: 2002
    ..The auditory and visual continuous performance tasks and the Stroop test will be used to further assess treatment efficacy. A larger neuropsychological battery will be used to assess the long term effects of MPH treatment. ..
  10. Pimozide Augmentation of Clozapine in Schizophrenia
    Joseph Friedman; Fiscal Year: 2007
    ..This study will provide sorely needed controlled data on the efficacy and safety of a clozapine combination treatment strategy involving adjunctive antipsychotic agents. [unreadable] [unreadable]..
  11. The Perception of Cancer Risk in Patients with Barrett's Esophagus
    Nicholas Shaheen; Fiscal Year: 2007
    ..The resultant study application will assess health-related quality of life, health-related anxiety and healthcare utilization as outcomes. [unreadable] [unreadable]..
  12. Epidemiologic Case-control Study of Barrett's Esophagus
    Nicholas Shaheen; Fiscal Year: 2005
    ..Finally, by comparing subjects with Barrett's to controls with reflux, and controlling for severs of reflux, the impact of a Barrett's diagnosis on quality of life and psychological stress may be seen. ..
  13. Estrogen, Stress and Dysfunction of Prefrontal Cortex
    Amy Arnsten; Fiscal Year: 2005
    ..This research will begin to reveal how estrogen amplifies the neurochemical cascades that lead to activation of CREB and dysfunction of the PFC during stress ..
  14. Evaluation of Stimulant Drugs
    Sharon Wigal; Fiscal Year: 2006
    ..Within-subject PK variability in time-course of serum concentration for each medication will be analyzed, and the time-response characteristics also will be estimated based on PD measures for methylphenidate. ..
  15. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2006
    ..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
  16. COGNITIVE LOSS WITH AGE--ROLE OF CORTICAL CATECHOLAMINES
    Amy Arnsten; Fiscal Year: 2007
    ..abstract_text> ..
  17. Cocaine Withdrawal and Pharmacotherapy Response
    Mehmet Sofuoglu; Fiscal Year: 2010
    ..This proposal, by testing the efficacy of carvedilol and investigating the influence of withdrawal severity on carvedilol's efficacy, may result in development of more effective treatments for cocaine addiction. ..
  18. GABA Medications for Tobacco Addiction
    Mehmet Sofuoglu; Fiscal Year: 2009
    ..The findings of this study will provide valuable information to develop new pharmacotherapies for smoking cessation. ..
  19. Behavioral Model of Contextual Attention in the Monkey
    J Jentsch; Fiscal Year: 2003
    ..The development of such an approach to modeling contextual aspects of attention, in particular, in animals should be a major advance linking pre-clinical psychopharmacological studies and treatment-based research for schizophrenia. ..
  20. Novel therapeutics for chronic pain
    Paul Wood; Fiscal Year: 2005
    ....
  21. PREVENTION OF CIGARETTE SMOKING IN ADHD YOUTH
    Joseph Biederman; Fiscal Year: 2001
    ..Since there are estimated to be 3.5 million children with ADHD and 20% have been shown to be smokers, targeting this group could potentially impact 700,000 children and adolescents. ..
  22. Collaborative Pediatric Bipolar Disorder Conference
    Joseph Biederman; Fiscal Year: 2007
    ..While the proposed conference does not intend to solve all outstanding problems associated with pediatric bipolar disorder, it will provide a forum to begin formulating a solution. ..
  23. Course of psychopathology in female youth: Analysis with extant longitudinal data
    Joseph Biederman; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  24. Adult Outcome of Attention Deficit Hyperactivity Disorder
    Joseph Biederman; Fiscal Year: 2007
    ..For these reasons, we expect the proposed work to clarify the course and outcome of ADHD. ..
  25. LONGITUDINAL FOLLOW UP OF ADHD GIRLS AND THEIR SIBLINGS
    Joseph Biederman; Fiscal Year: 2002
    ....
  26. Bipolar II Depression: Lithium, SSRI or the Combination
    Susan L McElroy; Fiscal Year: 2010
    ..We also hypothesize that the frequency of side effects will be significantly less in patients on SSRI monotherapy. Thus, secondary aims include assessment of patient satisfaction, which may affect compliance in the clinical setting. ..
  27. New Neural Targets for Opioid Use Disorders: Human Studies
    Sharon L Walsh; Fiscal Year: 2010
    ..Thus, these studies, conducted in healthy humans, will provide fundamental information regarding the potential for this system as a target for development of new treatment agents for opioid use disorders. ..
  28. Neural Dissection of Hyperactivity/Inattention in Autism
    Francisco Xavier Castellanos; Fiscal Year: 2010
    ..If successful, we will be able to better understand the types of brain mechanisms that are involved in hyperactivity and inattention in children with autism and then be able to use that information to guide targeted treatment studies. ..
  29. Validating Novel Familial Phenotypes of Drug Abuse
    Stephen Faraone; Fiscal Year: 2007
    ..State of the art statistical techniques will be employed. ..
  30. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  31. S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
    George Papakostas; Fiscal Year: 2008
    ..It is hoped that this project award will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator in this area. ..
  32. Analysis of an ADHD Whole Genome Association Scan
    Stephen Faraone; Fiscal Year: 2007
    ..All genotype data generated by the GAIN whole genome association scan will be made available to the scientific community by GAIN as soon as the genotypes are completed. [unreadable] [unreadable] [unreadable]..
  33. Methods of Optimal Depression Detection in Parkinson's
    Laura Marsh; Fiscal Year: 2009
    ....
  34. New Cycloadditions in Synthesis
    MARC SNAPPER; Fiscal Year: 2007
    ..Likewise, the cycloaddition provides access to libraries of untested, completely novel structures that may uncover unique opportunities in drug discovery and Chemical Biology. ..
  35. International Multi-Center ADHD Genetics Project
    Stephen Faraone; Fiscal Year: 2007
    ..abstract_text> ..
  36. 2/5-The Psychiatric GWAS Consortium: Integrated & Coordinated GWAS Meta-Analyses
    Stephen Faraone; Fiscal Year: 2008
    ..Finally, the PGC proposes to abide as fully as possible with the NIH's GWAS data sharing policies and we provide a detailed data sharing plan and timetable. [unreadable] [unreadable] [unreadable]..
  37. Evaluation of Novel Treatments for Stimulant Dependence
    Sharon Walsh; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  38. Stress and Marijuana Cue-Elicited Craving and Reactivity
    Aimee McRae; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  39. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2008
    ..This will be an important step for improving the lives of people with schizophrenia. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  40. GABAergic excitation in human hypothalamic hamartoma
    Jie Wu; Fiscal Year: 2007
    ..Knowledge about excitatory GABAA receptor function of HH neurons will also aid selection of superior strategies for pharmaceutical development to prevent and control human gelastic seizures. [unreadable] [unreadable]..
  41. TESTING THE VALIDITY OF ADULT ATTENTION DEFICIT DISORDER
    Stephen Faraone; Fiscal Year: 2002
    ..Thus, if founded, we expect that the proposed work will lead to a program of research that can both clarify the nosological complexities of adult ADHD and clarify the nature of genes that are risk factors for the disorder. ..
  42. ASYMMETRIC 1,2-ADDITIONS
    DAVID COLLUM; Fiscal Year: 2005
    ..Although the highly selective additions to the quinazolinones behave quite differently from the additions to ketones, the strategies and analytical methods used to study them will be similar. ..
  43. Cardiac-Related Mortality with Atypical Antipsychotics
    DEANNA KELLY; Fiscal Year: 2005
    ..This study is important as data on long-term health outcomes with atypical antipsychotics is lacking from the literature. ..
  44. CELLULAR INTERACTIONS OF BIOLOGICALLY ACTIVE AGENTS
    MARC SNAPPER; Fiscal Year: 2004
    ..For these reasons, further knowledge of the details of ligand interactions with membrane compounds should be of substantial benefit. ..
  45. JUVENILE ONSET OCD AS A MEANINGFUL DEVELOPMENT SUBTYPE
    Daniel Geller; Fiscal Year: 2003
    ..The clinical, scientific, and public health relevance of confirming or refuting these hypotheses is discussed. ..
  46. DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PD
    C Olanow; Fiscal Year: 2003
    ..abstract_text> ..
  47. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  48. AN ECOGENETIC STUDY OF ADHD
    Stephen Faraone; Fiscal Year: 2003
    ..Furthermore, no studies have used an ecogenetic approach to sharpen the accuracy of risk prediction. ..
  49. Multimeric Ligands for Targeting of Pancreatic Cancer
    Robert Gillies; Fiscal Year: 2005
    ..Although designed for PaAdo, these multimeric ligands could potentially be used against a wide variety of cancers. ..
  50. Factors in Drug Dependence
    Sharon Walsh; Fiscal Year: 2005
    ..abstract_text> ..
  51. New Cycloadditions in Synthesis
    MARC SNAPPER; Fiscal Year: 2006
    ....
  52. Nicotine & Ethanol Influences on Contextual Conditioning
    Thomas Gould; Fiscal Year: 2007
    ..Understanding the underlying neurobiology will not only further aid in this understanding but will also aid in developing treatments for alcoholism and nicotine addiction. [unreadable] [unreadable]..
  53. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  54. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  55. Blood-Brain Barrier Nutrient Transport
    Ian Simpson; Fiscal Year: 2006
    ..Taken together these studies will provide new information on the regulation of transport across the BBB and will further our understanding of nutrient and drug delivery to the brain [unreadable] [unreadable]..
  56. Neuroimaging of Children at Risk for Biopolar Disorder
    Kiki Chang; Fiscal Year: 2006
    ..Chang plans to become an independent investigator in the field of pediatric BD and thus contributing to the current knowledge of the neurobiology and development of BD. ..
  57. METHYLPHENIDATE STUDY IN YOUNG CHILDREN WITH PDD
    Jaswinder Ghuman; Fiscal Year: 2005
    ..The proposed training program will allow the candidate to acquire sufficient expertise to carry out future treatment intervention studies in a very specialized area. ..
  58. PILOT EXPLORATIONS OF ZINC EFFECTS IN ADHD
    L Arnold; Fiscal Year: 2007
    ..Outcome measures include parent/teacher-rated ADHD symptoms for phases 1&2, and amphetamine optimal dose for phase 3. Tissue zinc will be determined by 3 state-of-the-art assays. ..
  59. CHEMISTRY OF LITHIUM AMIDES
    DAVID COLLUM; Fiscal Year: 2003
    ..Overall, the lithium amides offer a promising opportunity to understand the complexities presented by organolithium chemistry. ..
  60. Psychopharmacology of Autism and related Disorders
    David Posey; Fiscal Year: 2007
    ..Towards the later years of the award, the candidate will have performed additional studies and applied for independent research funding. ..
  61. Eighth Nerve Stimulation for the Treatment of ADHD
    L Arnold; Fiscal Year: 2003
    ..We hypothesize that CMA stimulation will show a larger effect than simple rotary stimulation, significant compared to sham control. Sufficient sample size is assured by the Ohio State University's recruitment record. ..